MARY MCMANMON: Open Payments
NPI 1255363172 · ELKHART, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$367 in 20 payments from 8 companies in 2025. Trend: 2023 $457 · 2024 $330 · 2025 $367
Food & beverage: $367
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $200 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $32 |
| GlaxoSmithKline, LLC. | 2 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| Gilead Sciences, Inc. | 1 | $24 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
| Merck Sharp & Dohme LLC | 1 | $16 |
| Amgen Inc. | 1 | $15 |
Products named: VRAYLAR, JARDIANCE, TRELEGY ELLIPTA, ZENPEP, CAPLYTA, VAXELIS, REPATHA, MAVYRET.
Industry payments across IN — which companies pay providers there.
